Skip to content Skip to footer
Subscribe Now

VIEWPOINTS

VIEWPOINTS_Dr. Mourad Farouk Rezk_2023
Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on BLA Acceptance for BIIB800
Shots: Dr. Mourad spoke about the acceptance of aBLA for BIIB800, a Tocilizumab biosimilar candidate for several autoimmune diseases, including rheumatoid arthritis He briefed about the study design and results from the P-III trial which supported the BLA filing This interview focuses on Biogen's notable progress in addressing challenging immunologic conditions, offering potential solutions to…
July 10, 2023
VIEWPOINTS_Brian Ingram_2023
Brian Ingram, Director, Discovery & Translational Sciences at Metabolon Shares his Views on the Expansion of its Inflammation Portfolio
Shots: Brian briefed our readers about Metabolon’s inflammation portfolio expansion with the launch of new Targeted Panels studying cannabinoids, sphingolipids, and lipid mediators of inflammation including its Oxysterols Targeted Panel He also talked about Endocannabinoids and Sphingolipids and how Metabolon targeted panels are used for their measurements The interview highlights how Metabolon’s mission to deliver…
July 6, 2023
VIEWPOINTS_Michael Irizarry1_2023
Michael Irizarry, SVP, Clinical Research, Eisai Shared Insights on P-III Results from Clarity AD Study
Shots: Michael spoke about the P-III Clarity AD study evaluating Leqembi (lecanemab) for the treatment of mild cognitive impairment due to Alzheimer’s disease presented at CTAD 2022 He also talked about Eisai’s collaboration with Biogen for the co-commercialization and co-promotion of Lecanemab The interview gives an understanding of how Biogen develops and delivers innovative therapies…
July 4, 2023
VIEWPOINTS_Dr. Mourad Farouk Rezk1_2023
Dr. Mourad Farouk Rezk, Head of Global Medical & Development Biogen Biosimilars Shares Insights on Positive P-III Data for BIIB800 (Actemra biosimilar)
Shots : Dr. Mourad talked about the positive P-III data showing results for BIIB800, a Tocilizumab biosimilar candidate presented at the Annual European Congress of Rheumatology (EULAR 2022) He also spoke about the results of the 48-week analysis of the PROPER trial evaluating   adalimumab biosimilar, Imraldi, in patients with autoimmune diseases The interview highlights Biogen's…
June 27, 2023
VIEWPOINTS_Andrea Mugan_2023
Andrea Mugan, Global Franchise Head of DDR & GYN/GU Cancers, AstraZeneca Shares Insights on ‘Never Miss’ campaign
Shots: Andrea briefed PharmaShots about the global prostate cancer awareness ‘Never Miss’ campaign developed by AstraZeneca and MSD to help men understand their potential risk of developing prostate cancer He also talked about the increasing number of prostate cancer patients and how this campaign will help support those who may be impacted by prostate cancer…
June 22, 2023
VIEWPOINTS_John Orwin_2023
John Orwin, President, and CEO at Atreca Shares his Views on Developing Novel Therapies for Cancer
Shots: John spoke about the development of a T cell engaging bispecific antibody directed against a novel solid tumor target under Atreca’s existing collaboration with Xencor He also talked about how this joint program combines the Atreca-discovered antibody, APN-346958, with Xencor’s XmAb CD3 bispecific antibody platform The interview gives an understanding of Atreca’s focus on…
June 20, 2023
VIEWPOINTS_Philippe Halfon_2023
Philippe Halfon, President & Founder of Genoscience Pharma Shares Insights from the P-IIb Trial of Ezurpimtrostat to Treat Hepatocarcinoma
Shots: Philippe talked about the launch of the ABE-LIVER P-IIb study evaluating Ezurpimtrostat to treat hepatocarcinoma in combination with atezolizumab (an anti-PDL1) and bevacizumab (an antiangiogenic agent) He also gave a brief on the study design and talked about the efficacy of Ezurpimtrostat with atezolizumab & bevacizumab, compared to SOC alone The interview gives an…
June 15, 2023
VIEWPOINTS_Rui Avelar_2023
Rui Avelar, CMO and Head of R&D at Evolus Shares Insights from Interim P-II Data Results Evaluating an “Extra-Strength” Formulation of Jeuveau
Shots: Rui gave the details about the “extra-strength” formulation of Jeuveau. He highlighted the study design and results of the trial evaluating  Jeuveau. The data indicated that the “extra-strength” formulation of Jeuveau at 40U achieved a duration profile of 6 months or 26 weeks The data was presented at the 2023 IMCAS World Congress in…
June 13, 2023
Load more